KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Edgewell Personal Care (EPC) Research & Development (2016 - 2025)

Edgewell Personal Care (EPC) has disclosed Research & Development for 17 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 2.99% to $13.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.5 million through Dec 2025, down 1.71% year-over-year, with the annual reading at $57.6 million for FY2025, 1.37% down from the prior year.
  • Research & Development for Q4 2025 was $13.8 million at Edgewell Personal Care, down from $15.8 million in the prior quarter.
  • The five-year high for Research & Development was $16.3 million in Q3 2024, with the low at $12.8 million in Q4 2021.
  • Average Research & Development over 5 years is $14.4 million, with a median of $14.2 million recorded in 2021.
  • The sharpest move saw Research & Development increased 17.74% in 2021, then fell 6.85% in 2022.
  • Over 5 years, Research & Development stood at $12.8 million in 2021, then increased by 4.69% to $13.4 million in 2022, then fell by 0.75% to $13.3 million in 2023, then rose by 0.75% to $13.4 million in 2024, then rose by 2.99% to $13.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $13.8 million, $15.8 million, and $14.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.